- Home
- NUVB vs BRKL Comparison
NUVB vs BRKL Comparison
Compare NUVB & BRKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BRKL
- Stock Information
- Founded
- NUVB 2018
- BRKL 1871
- Country
- NUVB United States
- BRKL United States
- Employees
- NUVB N/A
- BRKL N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BRKL Savings Institutions
- Sector
- NUVB Health Care
- BRKL Finance
- Exchange
- NUVB Nasdaq
- BRKL Nasdaq
- Market Cap
- NUVB 837.0M
- BRKL 948.1M
- IPO Year
- NUVB N/A
- BRKL 1998
- Fundamental
- Price
- NUVB $3.89
- BRKL N/A
- Analyst Decision
- NUVB Strong Buy
- BRKL Buy
- Analyst Count
- NUVB 6
- BRKL 2
- Target Price
- NUVB $8.00
- BRKL $15.25
- AVG Volume (30 Days)
- NUVB 6.2M
- BRKL 884.6K
- Earning Date
- NUVB 11-05-2025
- BRKL 10-22-2025
- Dividend Yield
- NUVB N/A
- BRKL 4.93%
- EPS Growth
- NUVB N/A
- BRKL 2.47
- EPS
- NUVB N/A
- BRKL 0.88
- Revenue
- NUVB $14,355,000.00
- BRKL $345,393,000.00
- Revenue This Year
- NUVB $332.80
- BRKL $53.95
- Revenue Next Year
- NUVB $360.12
- BRKL $68.33
- P/E Ratio
- NUVB N/A
- BRKL $12.44
- Revenue Growth
- NUVB 900.35
- BRKL 2.90
- 52 Week Low
- NUVB $1.54
- BRKL $9.28
- 52 Week High
- NUVB $4.09
- BRKL $13.15
- Technical
- Relative Strength Index (RSI)
- NUVB 83.37
- BRKL 6.74
- Support Level
- NUVB $2.87
- BRKL $10.87
- Resistance Level
- NUVB $3.08
- BRKL $11.24
- Average True Range (ATR)
- NUVB 0.22
- BRKL 0.17
- MACD
- NUVB 0.08
- BRKL -0.68
- Stochastic Oscillator
- NUVB 86.52
- BRKL 0.00
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.